Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Atorvastatin for Cerebral Vascular Wall Damage Post-Thrombectomy
NCT05912686Phase 4Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of atorvastatin in ischemic stroke (2 arms), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Cerebral vascular wall damage. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05912686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912686.